IIOT-OXYS, Inc. Announces Appointment of Chandran Seshagiri as Interim Chief Technology Officer
CAMBRIDGE, MA / ACCESSWIRE / April 6, 2021 / IIOT-OXYS, Inc. (OTC PINK:$ITOX) announced the appointment of its new Interim Chief Technology Officer, Chandran Seshagiri.
Cliff Emmons, CEO of IIOT-OXYS, Inc., stated, "I'm pleased to announce the appointment of Chandran Seshagiri as our new Interim Chief Technology Officer (CTO). When we announced Chandran's appointment as our new Advisory Board Chairman in mid-March, we noted he has made significant contributions to our past successful projects and continues to lead our algorithm development efforts on current and future projects. His passion for transforming complex signals into actionable information started with his work at the Harvard-MIT Division of Health Sciences and Technology, where he completed his Ph.D. Chandran's work on neurostimulation technology and EEG-based algorithms for personalized anesthesia medication delivery has translated well to the time series data and predictive analyses required for Smart Manufacturing and Structural Health Monitoring applications for IIOT-OXYS, Inc.'s customers. In his new position as Interim CTO, Chandran will also continue to lead our Advisory Board."
"Tony Coufal, our former CTO, has decided to leave the company to pursue other opportunities. We thank him for all of his contributions to the company over the past three years. We wish him continued success in his future endeavors. This transition of leadership in our CTO position reflects the greater focus the company is placing on Artificial Intelligence (AI) and Machine Learning (ML) in its business model. Our customers value our ability to transform data into actionable insights and is the driving factor for securing two new Non-Disclosure Agreements (NDA) with two New England Biotech Startups in the first quarter of this year. An NDA is the first step of our customer engagement process. Chandran also has been instrumental in building a strong technical relationship with our previously disclosed collaboration partner, Aingura IIoT, S.L. This collaboration, along with the previously disclosed completion of a successful pilot program with a Fortune 500 Pharma company, have allowed the Company and its partner to prepare use cases to renew engagements with all of the Company's earlier prospects and reach out to new ones. Our sales and marketing efforts continue to result in expanding our key targeted markets and serving a diverse group of clients. We expect these agreements to lead to new business in due time.", continued Mr. Emmons.
